Epigenetics modifications and Subclinical Atherosclerosis in Obstructive Sleep Apnea: The EPIOSA study

BMC Pulmonary Medicine

Luis Ros⁶  Jose P Cubero⁷  Marta Forner⁷  Victoria Gil⁷  Isabel Villar⁷  Jose A Garcia-Erce³  Begoña Gallego⁴  Javier Godino⁵  Luis Varona²  Arianne Sanz²  Rosa Bolea²  Inmaculada Martin-Burriel²  Marta Andres⁷  Santiago J Carrizo⁴  Teresa Martin⁴  Jorge Artal¹  Jose M Marin⁷ 

[1] Neurology Unit, Hospital Universitario Miguel Servet, Zaragoza, Spain;Department of Anatomy, Embriology and Genetics, Faculty of Veterinary, Zaragoza, Spain;Hematology Service, Hospital San Jorge, Huesca, Spain;Respiratory Service, Hospital Universitario Miguel Servet, I-3 Avda Isabel la Católica, 50006 Zaragoza, Spain;Cytometry Unit, Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain;Radiology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain;Translational Research Unit, Hospital Universitario Miguel Servet, Zaragoza, Spain

关键词: Epigenetics;    Systemic inflammation;    Subclinical atherosclerosis;    Sleep apnea;   

Others  :  862703
DOI  :  10.1186/1471-2466-14-114

 received in 2014-06-05, accepted in 2014-07-03,  发布年份 2014

【 摘 要 】

Background

Obstructive sleep apnea (OSA) is associated with increased risk for cardiovascular morbidity and mortality. Epidemiological and animal models studies generate hypotheses for innovative strategies in OSA management by interfering intermediates mechanisms associated with cardiovascular complications. We have thus initiated the Epigenetics modification in Obstructive Sleep Apnea (EPIOSA) study (ClinicalTrials.gov identifier: NCT02131610).

Methods/design

EPIOSA is a prospective cohort study aiming to recruit 350 participants of caucasian ethnicity and free of other chronic or inflammatory diseases: 300 patients with prevalent OSA and 50 non-OSA subjects. All of them will be follow-up for at least 5 years. Recruitment and study visits are performed in single University-based sleep clinic using standard operating procedures. At baseline and at each one year follow-up examination, patients are subjected to a core phenotyping protocol. This includes a standardized questionnaire and physical examination to determine incident comorbidities and health resources utilization, with a primary focus on cardiovascular events. Confirmatory outcomes information is requested from patient records and the regional Department of Health Services. Every year, OSA status will be assessed by full sleep study and blood samples will be obtained for immediate standard biochemistry, hematology, inflammatory cytokines and cytometry analysis. For biobanking, aliquots of serum, plasma, urine, mRNA and DNA are also obtained. Bilateral carotid echography will be performed to assess subclinical atherosclerosis and atherosclerosis progression. OSA patients are treated according with national guidelines.

Discussion

EPIOSA will enable the prospective evaluation of inflammatory and epigenetics mechanism involved in cardiovascular complication of treated and non-treated patients with OSA compared with non OSA subjects.

【 授权许可】

   
2014 Marin et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Young T, Peppard PE, Gottlieb DJ: Epidemiology of obstructive sleep apnea. A population health perspective. Am J RespirCrit Care Med 2002, 165:1217-1239.
• [2]Marin JM, Carrizo SJ, Vicente E, Agusti AG: Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005, 365:1046-1053.
• [3]Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, Martínez-Alonso M, Carmona C, Barceló A, Chiner E, Masa JF, Gonzalez M, Marin JM, Garcia-Rio F, Diaz de Aturi J, Teran J, Mayos M, de la Peña M, Monasterio C, del Campo F, Montserrat JM, Spanish Sleep And Breathing Network: Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA 2012, 307:2161-2168.
• [4]Marin JM, Agusti A, Villar I, Forner M, Nieto D, Carrizo SJ, Barbé F, Vicente E, Wei Y, Nieto FJ, Jelic S: Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA 2012, 307:2169-2176.
• [5]Gottlieb DJ, Yenokyan G, Newman AB, O´Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, Shahar E: Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 2010, 122:352-360.
• [6]Redline S, Yenokyan G, Gottlieb DJ, Shahar E, O’Connor GT, Resnick HE, Dieter-West M, Sandres MH, Wolf PA, Geragthy EM, Lebowith M, Punjabi NM: Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med 2010, 182:269-277.
• [7]Yokoe T, Minoguchi K, Matsuo H, Oda N, Minogucho H, Yoshino G, Hirano T, Adachi M: Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003, 107:1129-1134.
• [8]Pack AI, Gislason T: Obstructive sleep apnea and cardiovascular disease: a perspective and future directions. Prog Car Dis 2009, 51:434-451.
• [9]Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
• [10]Barcelo A, Barbe F, Llompart E, Mayoralas LR, Ladaria A, Bosch M, Agusti AG: Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Med 2004, 117:118-121.
• [11]Taheri S, Austin D, Lin L, Nieto FJ, Young T, Mignot E: Correlates of serum C-reactive protein (CRP)–no association with sleep duration or sleep disordered breathing. Sleep 2007, 30:991-996.
• [12]Arnardottir ES, Maislin G, Schwab RJ, Staley B, Benediktsdottir B, Olafsson I, Juliusson S, Romer M, Gislason T, Pack AI: The interaction of obstructive sleep apnea and obesity on the inflammatory markers c-reactive protein and interleukin-6: the Icelandic Sleep Apnea Cohort. Sleep 2012, 35(7):921-932.
• [13]Jelic S, Lederer DJ, Adams T, Padeletti M, Colombo PC, Factor PH, Le Jemtel TH: Vascular inflammation in obesity and sleep apnea. Circulation 2010, 121(8):1014-1021.
• [14]Watson JA, Watson CJ, McCann A, Baugh J: Epigenetics, the epicenter of the hypoxic response. Epigenetics 2010, 5:293-296.
• [15]Stenvinkel P, Karimi M, Johansson S, Axelsson J, Suliman M, Lindholm B, Heimbuürger O, Barany P, Alvestrand A, Nordfords L, Qureshi AR, Ekström TJ, Schalling M: Impact of inflammation on epigenetic DNA methylation: a novel risk factor for cardiovascular disease? J Intern Med 2007, 261:488-499.
• [16]Kim J, Bhattacharjee R, Khalyfa A, Kheirandish-Gozal L, Capdevila OS, Wang Y, Gozal D: DNA methylation in inflammatory genes among children with obstructive sleep apnea. Am J Respir Crit Care Med 2012, 185:330-338.
• [17]Klingenberg R, Gerdes N, Badeau RM, Gisterå A, Strodthoff D, Ketelhuth DF, Lundberg AM, Rudling M, Nilsson SK: Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. J Clin Invest 2013, 123:1323-1334.
• [18]Grupo Español de Sueño: Consenso nacional sobre el síndrome de apneas-hipopneas del sueño. Arch Bronconeumol 2005, 41(Suppl 4):1-100.
• [19]Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991, 14:540-545.
• [20]Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Rocella EJ: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
• [21]Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino OR, Pellegrino R, Viegi G, Wanger J: ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
• [22]Masa JF, Jiménez A, Durán J, Capote F, Monasterio C, Mayos M, Terán J, Hernández L, Barbé F, Maimó A, Rubio M, Montserrat JM: Alternative methods of titrating continuous positive airway pressure: a large multicenter study. Am J Respir Crit Care Med 2004, 170(11):1218-1224.
• [23]Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203:1701-1711.
• [24]Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, Delano D, Zhang L, Schroth GP, Gunderson KL, Fan JB, Shen R: High density DNA methylation array with single CpG site resolution. Genomics 2011, 98:288-295.
• [25]Bock C: Analysing and interpreting DNA methylation data. Nat Rev Genet 2012, 13:705-719.
• [26]Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005, 33:e179.
• [27]Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
• [28]Muntendam P, McCall C, Sanz J, Falk E, Fuster V: The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease: study design and objectives. Am Heart J 2010, 160:49-57.
• [29]Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman R, Warach S, Launer LJ, Van Buchem MA, Breteler MM, Microbleed Study Group: Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009, 8:165-174.
• [30]Tan HL, Gozal D, Wang Y, Bandla HP, Bhattacharjee R, Kulkarni R, Kheirandish-Gozal L: Alterations in circulating T-cell lymphocyte populations in children with obstructive sleep apnea. Sleep 2013, 36:913-922.
• [31]Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF: Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2007, 176:706-712.
• [32]Hermansson A, Ketelhuth DF, Strodthoff D, Wurm M, Hansson EM, Nicoletti A, Paulsson-Berne G, Hansson GK: Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med 2010, 207(5):1081-1093.
• [33]Olson NC, Doyle MF, Swords N, Huber SA, Psaty BM, Kronmal RA, Tracy RP: Decrease naïve and increased memory CD4+ T cells are associated with subclinical atherosclerosis: the Milti-Ethnic Study of Atherosclerosis. PLoS One 2013, 8(8):e71498.
• [34]Hansson GK, Hermansson A: The immune system in atherosclerosis. Nat Immunol 2011, 12:204-212.
• [35]Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299(5609):1057-1061.
• [36]Jia L, Zhu L, Wang JZ, Wang XJ, Chen JZ, Song L, Wu YJ, Sun K, Yuan ZY, Hui R: Methylation of FOXP3 in regulatory T cells is related to the severity of coronary artery disease. Atherosclerosis 2013, 228:346-352.
• [37]Nácher M, Farré R, Montserrat JM, Torres M, Navajas D, Bulbena O, Serrano-Mollar A: Biological consequences of oxygen desaturation and respiratory effort in an acute animal model of obstructive sleep apnea (OSA). Sleep Med 2009, 10:892-897.
• [38]Nieto FJ, Herrington DM, Redline S, Benjamin EJ, Robbins JA: Sleep apnea and markers of vascular endothelial function in a large community sample of older adults. Am J Respir Crit Care Med 2004, 169:354-360.
• [39]Kylintireas I, Craig S, Nethononda R, Kohler M, Francis J, Choudhury R, Stradling J, Neubauer S: Atherosclerosis and arterial stiffness in obstructive sleep apnea–a cardiovascular magnetic resonance study. Atherosclerosis 2012, 222:483-489.
• [40]Tahini S, Austin D, Lin L, Nieto FJ, Young T, Mignot E: Correlates of C-reactive protein (CRP) – no association with sleep duration or sleep disordered breathing. Sleep 2007, 30:991-996.